Abiraterone Acetate CAS 154229-18-2 (COPP/local GMP/DMF) Anti-cancer drugs
02
introduce
Abiraterone Acetate is a prodrug of abiraterone, a potent selective CYP17A1 inhibitor. It blocks systemic androgen biosynthesis and serves as the first-line core API for metastatic castration-resistant prostate cancer treatment.
Our strict quality control ensures consistent batch performance for pharmaceutical production needs.
02
Physical and chemical properties
Abiraterone Acetate possesses key physical and chemical characteristics as follows:
- Melting Point: 127-130 °C
- Boiling Point: 506.7±50.0 °C
- Density: 1.14±0.1 g/cm³
- Protein Binding: 99.8%
- Biological Half-life: ~15 hours (active metabolite)
- Storage Conditions: Sealed in dry, -20 °C
- Solubility: Slightly soluble in chloroform, DMSO and methanol
Superior Oral Bioavailability
Optimized lipophilicity compared to abiraterone, significantly improving gastrointestinal absorption.
Optimized lipophilicity compared to abiraterone, significantly improving gastrointestinal absorption.
Irreversible CYP17A1 Inhibition
IC₅₀ of 2.9 nM (17α-hydroxylase) and 4 nM (C17,20-lyase), blocking androgen synthesis from all sources.
Proven Clinical Survival Benefit
Extends overall survival in both pre- and post-chemotherapy metastatic prostate cancer patients.
Convenient Oral Administration
Once-daily dosing with prednisone, excellent patient compliance for long-term treatment.
Well-Characterized Metabolism
Rapidly and completely hydrolyzed to active abiraterone in vivo, predictable pharmacokinetic profile.
Prostate Cancer Therapeutics
Core raw material for first-line treatment of metastatic castration-resistant prostate cancer (mCRPC).
Used in formulations for metastatic high-risk castration-sensitive prostate cancer (mCSPC) in combination with androgen deprivation therapy.
Core raw material for first-line treatment of metastatic castration-resistant prostate cancer (mCRPC).
Used in formulations for metastatic high-risk castration-sensitive prostate cancer (mCSPC) in combination with androgen deprivation therapy.
Clinical Research Applications
Investigational API for early-stage prostate cancer and advanced breast cancer therapy development.
Abiraterone Acetate is the clinically preferred prodrug form of abiraterone, with superior bioavailability and established therapeutic efficacy. As the cornerstone of advanced prostate cancer treatment, it remains an essential oncology API with ongoing research expanding its clinical applications.
Contact our team today for sample requests, technical specifications and bulk order inquiries—we’re committed to providing efficient and customized pharmaceutical material solutions for you.
Contact our team today for sample requests, technical specifications and bulk order inquiries—we’re committed to providing efficient and customized pharmaceutical material solutions for you.